ClinicalTrials.gg
CompletedNCT00813072Updated Mar 2, 2012

Study of PEP02, Irinotecan or Docetaxel in Gastric or Gastroesophageal Junction Adenocarcinoma

A Phase 2 interventional study of PEP02 and irinotecan in Stomach Neoplasms and Esophageal Neoplasms, sponsored by PharmaEngine. Completed at 22 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-03-02.

Sponsored by PharmaEngine · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
135
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 141 studies in Stomach Neoplasms with a site in Taiwan — 26 open to participants now, 43 under way, 10 of them phase 3. Stomach Neoplasms · Taiwan.

Enrollment
70th of 128
135 · median 154
Started
2007
with 4 others
Phase 2
38 of 141
7 open now
Registered
20th of 141
by date

Among the 141 studies in Stomach Neoplasms with a site in Taiwan, this one is the 70th largest by enrollment of the 128 interventional ones that give a count, is one of 5 that started in 2007, is one of 38 in phase 2, and was the 20th registered.

Stomach Neoplasms

3,403 studies on the registry are indexed under Stomach Neoplasms; 995 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

26 of the 141 studies in Stomach Neoplasms with a site in Taiwan are open now. Recruiting first, the newest first:

21 more — sign in →

All 26 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 69 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 141 studies in Stomach Neoplasms with a site in Taiwan, or all of them as a file.
02

Study summary

The purpose of this study is to assess objective tumor response in the single agent treatment of PEP02, irinotecan, or docetaxel for locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma

Read the detailed description

Palliative chemotherapy has been shown to improve survival compared with best supportive care alone in patients with unresectable or recurrent gastric cancer. There is no standard second-line chemotherapy for advanced gastric cancer and no randomized-controlled trial data suggest a benefit of second-line chemotherapy compared with supportive care alone. Response rates of second-line therapy in phase II trials are similar to those seen for other cancers that are more commonly retreated. Combination therapy may achieve higher response rates than single agents, however, the survival outcome are the same. In addition, data suggest that patients may obtain symptomatic benefits from second-line therapy. In comparison to the toxicity profile of single agent with combination regimen, patients are more tolerable to single agent therapy than combination.

Based on the previous clinical experience in second line chemotherapy of advanced gastric cancer, the single agent of PEP02, irinotecan and docetaxel are selected as the regimens for this randomized phase II study. The efficacy and toxicity outcome of the three-arm design will be a valuable reference for future combination therapy or phase III study design.

03

Conditions studied

  • Stomach Neoplasms
  • Esophageal Neoplasms

Keywords

  • Gastric Cancer
  • Stomach Cancer
  • Gastroesophageal
  • Gastroesophageal Junction
  • Esophageal Cancer
  • phase II
  • PEP02
  • randomization
  • randomisation
  • adenocarcinoma
  • locally advanced
  • metastatic
  • simon's two
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed locally advanced (unresectable) or adenocarcinoma of gastric or gastroesophageal junction
  • Failed to only one systemic chemotherapy for locally advanced or metastatic disease, including patients whose diseases recur within 6 months after (neo) chemotherapy. Chemotherapy administered with concurrent radiotherapy is NOT considered as systemic chemotherapy.
  • Have at least one according to the criteria
  • Aged above or equal to 18 years, at the time of acquisition of
  • With performance status 0, 1, or 2
  • equal to or more than 3 months
  • With adequate organ and marrow function as defined below:
  • With ability to understand and the willingness to sign a written Informed Consent Form

Exclusion criteria

Exclusion Criteria:

  • Had systemic chemotherapy within 3 weeks before the commencement of study treatment
  • Had radiotherapy within 4 weeks before the commencement of study treatment
  • With known
  • With active multiple cancers or had treatment for other carcinomas within the last five years, except cured non-melanoma skin and treated in-situ cervical cancer
  • With prior irinotecan or taxane (paclitaxel, docetaxel) treatment
  • Have received irradiation affecting > 30% of the active bone marrow
  • Had major surgery within 4 weeks of the start of study treatment (laparotomy, line placement is not considered major surgery)
  • Have not recovered from prior treatments
  • With preexisting peripheral neuropathy > grade 2
  • With history of allergic reaction to liposome product or other drugs formulated with polysorbate
  • With uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, active gastrointestinal bleeding, watery stools, central nervous system disorders or psychiatric illness/social situation that would limit compliance with study requirements or judged to be ineligible for the study by the investigator
  • Have received any agents within 3 weeks preceding the start of study treatment
  • Pregnant or breastfeeding females (a pregnancy test must be performed on all female patients who are of before entering the study, and the result must be negative)
  • With intestinal obstruction
  • Have received St. John's Wort, inducing anticonvulsants (phenytoin, phenobarbital, and carbamazepine), rifampin and rifabutin within two weeks, or ketoconazole, itraconazole, troleandomycin, erythromycin, diltiazem and verapamil within one week before the administration of study medications
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
135 participants (actual)

Study arms

  • Experimental
    1. PEP02

    liposome irinotecan

    Drug: PEP02

  • Active comparator
    2. irinotecan

    Drug: irinotecan

  • Active comparator
    3. docetaxel

    Drug: docetaxel

Interventions

  • DrugPEP02

    120 mg/m2, IV infusion for 90 minutes on day 1 of each 21 day as a treatment cycle. Number of Cycles: until progression or unacceptable toxicity develops.

    Also known as: liposome irinotecan

  • 300 mg/m2, IV infusion on day 1 of each 21 day as a treatment cycle. Number of Cycles: until progression or unacceptable toxicity develops.

    Also known as: Campto

  • 75 mg/m2, IV infusion for 60 minutes on day 1 of each 21 day as a treatment cycle. Number of Cycles: until progression or unacceptable toxicity develops.

    Also known as: Taxetere

06

What researchers measure

Primary outcomes

  1. objective tumor response

Secondary outcomes

  1. progression-free survival, duration of tumor response, time to progression, time to treatment failure, disease control rate, 1-year survival rate,and overall survival; pharmacokinetics and pharmacogenetics of PEP02 and irinotecan

07

Study locations

22 sites
  • Clinical Hospital Mostar
    Mostar, 36 000, Bosnia and Herzegovina
  • Clinical Centre University of Sarajevo
    Sarajevo, 71 000, Bosnia and Herzegovina
  • University Hospital Centre Rijeka
    Rijeka, 51 000, Croatia
  • University Hospital Centre Dubrava
    Zagreb, 10 000, Croatia
  • University Hospital Centre Zagreb
    Zagreb, 10 000, Croatia
  • Samsung Medical Center
    Seoul, 135-710, Korea, Republic of
  • Asan Medical Center
    Seoul, 138-736, Korea, Republic of
  • National Cancer Center
    Seoul, 410-769, Korea, Republic of
  • Hospital Universitario Vall d'Hebron
    Barcelona, 08035, Spain
  • Hospital General Universitario de Elche
    Elche, 03203, Spain
  • Hospital Clínico San Carlos
    Madrid, 28040, Spain
  • Hospital Universitario Marques de Valdecilla
    Santander, 39008, Spain
  • Chang Gung Memorial Hospital - Chiayi
    Chiayi, Taiwan
  • Chang Gung Memorial Hospital - LinKou
    LinKou, Taiwan
  • National Cheng Kung University Hospital
    Tainan, 704, Taiwan
  • Taipei Veterans General Hospital
    Taipei, 112, Taiwan
  • Mackay Memorial Hospital
    Taipei, 25115, Taiwan
  • Addenbrookes Hospital Oncology Center
    Cambridge, CB2 2QQ, United Kingdom
  • Guy's & St Thomas' NHS Foundation Trust
    London, SE19RT, United Kingdom
  • Kent Oncology Centre, Maidstone Hospital
    Maidstone, ME16 9QQ, United Kingdom
  • Southampton University Hospital
    Southampton, SO16 6YD, United Kingdom
  • The Royal Marsden Hospital
    Surrey, SM2 5PT, United Kingdom
08

References and documents

Publications

  • Roy AC, Park SR, Cunningham D, Kang YK, Chao Y, Chen LT, Rees C, Lim HY, Tabernero J, Ramos FJ, Kujundzic M, Cardic MB, Yeh CG, de Gramont A. A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma. Ann Oncol. 2013 Jun;24(6):1567-73. doi: 10.1093/annonc/mdt002. Epub 2013 Feb 13. PubMed 23406728 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2007, a primary completion of Jul 2010 and a completion of Dec 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2008
First posted
Dec 22, 2008
Start
Nov 2007
Primary completionActual
Jul 2010
CompletionActual
Dec 2010
Last update
Mar 2, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00813072
Lead sponsor
PharmaEngine
Responsible party
Sponsor
First posted
Dec 22, 2008
Start date
Nov 2007
Primary completion
Jul 2010
Completion
Dec 2010
Last update
Mar 2, 2012

Study contacts

David Cunningham
principal investigator · The Royal Marsden Hospital, London & Surrey, UK

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Irinotecan sucrosofate

Start the discussion